Bicara Therapeutics (BCAX) News Today $11.45 +0.07 (+0.62%) Closing price 04:00 PM EasternExtended Trading$11.46 +0.01 (+0.09%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Norges Bank Purchases Shares of 70,000 Bicara Therapeutics Inc. (NASDAQ:BCAX)Norges Bank acquired a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 70,000 shares of the company's stock, valued at approximaApril 14 at 3:32 AM | marketbeat.comHC Wainwright Issues Pessimistic Estimate for BCAX EarningsBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for Bicara Therapeutics in a research note issued to investors on Monday, April 7th. HC Wainwright analyst R. Burns now expects that the company will post earnApril 12 at 7:04 AM | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year Low - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low - Time to Sell?April 12 at 5:15 AM | marketbeat.comHC Wainwright Expects Lower Earnings for Bicara TherapeuticsApril 12 at 1:39 AM | americanbankingnews.comAlliancebernstein L.P. Increases Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX)Alliancebernstein L.P. increased its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 16.0% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 821,264 shares of the company's stock after buying an additional 113,261 shares during the quarter.April 11, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading 10.8% Higher - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Trading 10.8% Higher - Here's What HappenedApril 10, 2025 | marketbeat.comHC Wainwright Cuts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $44.00HC Wainwright reduced their target price on Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating for the company in a research note on Monday.April 9, 2025 | marketbeat.comHC Wainwright Has Lowered Expectations for Bicara Therapeutics (NASDAQ:BCAX) Stock PriceApril 8, 2025 | americanbankingnews.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives $36.67 Average Target Price from BrokeragesApril 8, 2025 | americanbankingnews.comBicara Therapeutics price target lowered to $44 from $45 at H.C. WainwrightApril 7, 2025 | msn.comBuy Rating Affirmed for Bicara Therapeutics Inc. Amid Promising Clinical Data and Financial StabilityApril 7, 2025 | tipranks.comBicara Therapeutics Inc. (NASDAQ:BCAX) Given Average Rating of "Buy" by AnalystsShares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been given an average rating of "Buy" by the eight brokerages that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The aveApril 7, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Hits New 12-Month Low - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week Low - Should You Sell?April 6, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 3.2% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 3.2% - Should You Sell?April 4, 2025 | marketbeat.comResearch Analysts Set Expectations for BCAX FY2025 EarningsBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Bicara Therapeutics in a research note issued on Monday, March 31st. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($1.8April 3, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Shares Gap Down - Should You Sell?April 2, 2025 | marketbeat.comCantor Fitzgerald maintains Overweight on Bicara Therapeutics stockApril 2, 2025 | uk.investing.comQ1 EPS Estimate for Bicara Therapeutics Reduced by AnalystBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Research analysts at Wedbush reduced their Q1 2025 earnings estimates for shares of Bicara Therapeutics in a research note issued to investors on Thursday, March 27th. Wedbush analyst D. Nierengarten now expects that the company will post earMarch 31, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Announces Earnings Results, Misses Estimates By $0.08 EPSBicara Therapeutics (NASDAQ:BCAX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08).March 29, 2025 | marketbeat.comBicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 29, 2025 | finanznachrichten.deBicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from WedbushWedbush reiterated an "outperform" rating and set a $31.00 price objective on shares of Bicara Therapeutics in a report on Thursday.March 28, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Up 5.7% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Trading Up 5.7% - What's Next?March 28, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Charles Schwab Investment Management Inc. acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund acquired 156,784 shares of the company's stock, valued at approximately $2,731,000. Charles ScMarch 28, 2025 | marketbeat.comBicara Therapeutics price target raised to $48 from $47 at StifelMarch 28, 2025 | markets.businessinsider.comBicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 27, 2025 | globenewswire.comBank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)Bank of New York Mellon Corp acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 40,268 shares of the company's stock, valuedMarch 27, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 6.6% - Here's What HappenedBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 6.6% - Time to Sell?March 26, 2025 | marketbeat.comBicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025March 25, 2025 | globenewswire.comBicara Therapeutics (NASDAQ:BCAX) Trading Up 5.5% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Stock Price Up 5.5% - Should You Buy?March 21, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 5.7% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Shares Down 5.7% - What's Next?March 19, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Invests $647,000 in Bicara Therapeutics Inc. (NASDAQ:BCAX)Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 38,035 shares of the company's stock, valued at approximately $647,000. SkandinaviskaMarch 18, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Given "Overweight" Rating at Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating and set a $13.01 price target on shares of Bicara Therapeutics in a research note on Thursday.March 14, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sees Strong Trading Volume - Time to Buy?Bicara Therapeutics (NASDAQ:BCAX) Sees Strong Trading Volume - What's Next?March 13, 2025 | marketbeat.comCompanies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In GrowthMarch 12, 2025 | finance.yahoo.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 7% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 7% - Time to Sell?March 12, 2025 | marketbeat.comBicara Therapeutics management to meet with Cantor FitzgeraldMarch 11, 2025 | markets.businessinsider.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from BrokeragesBicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been assigned an average recommendation of "Buy" from the eight analysts that are covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendationMarch 11, 2025 | marketbeat.com19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Rhumbline AdvisersRhumbline Advisers bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 19,008 shares of the company's stock, valued at approximately $331,000. Several otheMarch 10, 2025 | marketbeat.comBicara Therapeutics Inc.'s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12thBicara Therapeutics' (NASDAQ:BCAX - Get Free Report) lock-up period is set to expire on Wednesday, March 12th. Bicara Therapeutics had issued 17,500,000 shares in its public offering on September 13th. The total size of the offering was $315,000,000 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.March 5, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 7.5% - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 7.5% - Here's WhyMarch 4, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Up 6.7% - Should You Buy?Bicara Therapeutics (NASDAQ:BCAX) Shares Up 6.7% - Here's WhyMarch 1, 2025 | marketbeat.comBicara Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 24, 2025 | globenewswire.comBicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on TuesdayBicara Therapeutics (NASDAQ:BCAX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 21, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 4.5% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Shares Down 4.5% - Should You Sell?February 19, 2025 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Given Consensus Recommendation of "Buy" by BrokeragesShares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have earned a consensus recommendation of "Buy" from the eight brokerages that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buFebruary 14, 2025 | marketbeat.comStifel Nicolaus Sticks to Its Buy Rating for Bicara Therapeutics Inc. (BCAX)February 12, 2025 | markets.businessinsider.comBicara Therapeutics announces first patients dosed in FORTIFI-HN01 trialFebruary 12, 2025 | markets.businessinsider.comBicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaFebruary 11, 2025 | globenewswire.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 8.6% - Time to Sell?Bicara Therapeutics (NASDAQ:BCAX) Trading Down 8.6% - Here's WhyFebruary 11, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Up 7.3% - Still a Buy?Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.3% - What's Next?February 10, 2025 | marketbeat.com Remove Ads Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAX Media Mentions By Week BCAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAX News Sentiment▼0.090.80▲Average Medical News Sentiment BCAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAX Articles This Week▼114▲BCAX Articles Average Week Remove Ads Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MIRM News Today VCEL News Today BHC News Today BHVN News Today TARS News Today AAPG News Today BLTE News Today NAMS News Today MTSR News Today ARQT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
